Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells 42,841 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 42,841 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $41.49, for a total transaction of $1,777,473.09. Following the transaction, the chief financial officer directly owned 31,086 shares in the company, valued at approximately $1,289,758.14. This trade represents a 57.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Mark Ragosa also recently made the following trade(s):

• On Wednesday, November 12th, Mark Ragosa sold 19,900 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $40.94, for a total value of $814,706.00.
• On Tuesday, October 28th, Mark Ragosa sold 100 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.00, for a total value of $4,100.00.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded down $0.59 during trading hours on Wednesday, reaching $40.55. The company’s stock had a trading volume of 279,546 shares, compared to its average volume of 602,565. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $42.98. The stock has a market cap of $3.07 billion, a PE ratio of 90.11 and a beta of 0.02. The company’s 50-day moving average is $39.67 and its two-hundred day moving average is $34.24.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.08). The company had revenue of $180.86 million during the quarter, compared to analysts’ expectations of $166.64 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. Kiniksa Pharmaceuticals International’s quarterly revenue was up 61.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.18) EPS. Equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on KNSA shares. TD Cowen assumed coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They set a “buy” rating and a $60.00 price objective on the stock. The Goldman Sachs Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Wednesday, October 8th. Wedbush restated an “outperform” rating and issued a $48.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, December 2nd. Finally, Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $52.00.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG grew its position in shares of Kiniksa Pharmaceuticals International by 177.1% during the first quarter. Deutsche Bank AG now owns 394,522 shares of the company’s stock worth $8,762,000 after buying an additional 252,125 shares in the last quarter. Invesco Ltd. boosted its stake in Kiniksa Pharmaceuticals International by 137.4% during the 1st quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock valued at $744,000 after acquiring an additional 19,384 shares during the last quarter. Savant Capital LLC acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth $398,000. Vanguard Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock valued at $74,606,000 after purchasing an additional 151,604 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in Kiniksa Pharmaceuticals International by 30.4% in the first quarter. Wellington Management Group LLP now owns 91,032 shares of the company’s stock worth $2,022,000 after purchasing an additional 21,219 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.